Medigen Biotechnology Return on Equity

Medigen Biotechnology (3176.TWO) currently reports a ROE of -17.09%. That is below the Healthcare sector average of 11.15%. Use the charts on this page to explore Medigen Biotechnology's ROE history and peer comparisons.

Medigen Biotechnology's ROE of -17.09% is lower than the Healthcare sector average of 11.15%. That is roughly 253.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Medigen Biotechnology's current -17.09% should be judged against Healthcare norms (sector average: 11.15%) and against 3176.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -17.09%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Medigen Biotechnology, and consider following 3176.TWO for alerts when major investors trade the stock.

Medigen Biotechnology is classified in the Healthcare sector. On ROE, it currently shows -17.09% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 3176.TWO with unrelated industries.